As the cGAS/STING pathway is frequently suppressed or defective in a variety of cancers (18, 19, 23), the anti-tumor activity of FOLFOX, anti-PD-1/PD-L1 or their combination may show reduced efficacy in patients with defective cGAS/STING signaling. Here, STING1 is linked to cancer.